logo
logo

ElevateBio Scales Disruptive Cell and Gene Therapy Business Model with $525 Million Series C Financing

Mar 15, 2021over 4 years ago

Amount Raised

$525 Million

Round Type

series c

Cambridge

Description

ElevateBio, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, today announced it has raised $525 million in a Series C financing. ElevateBio has created a new disruptive business model addressing the most pressing challenges in the field of cell and gene therapy. With an unprecedented suite of next generation-enabling technologies; including gene editing, induced pluripotent stem cells, and protein, viral, and cellular engineering; the company is changing the way the field advances cell and gene therapies. ElevateBio is positioned to power the industry’s most promising therapies with an “Elevate Inside” approach by democratizing access to its technologies, and using ElevateBio BaseCamp (a technology-enabled process development and CGMP manufacturing capability) to advance transformative therapies across the entire industry

Company Information

Company

Elevate Bio:

Location

Cambridge, Maryland, United States

About

ElevateBio is headquartered in Cambridge, Mass, with ElevateBio BaseCamp located in Waltham, Mass. For more information, visit us at www.elevate.bio, or follow Elevate on LinkedIn, Twitter, or Instagram.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech